Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort

BACKGROUND: CDKN2A‐p16‐Leiden mutation carriers have a high lifetime risk of developing pancreatic ductal adenocarcinoma (PDAC), with very poor survival. Surveillance may improve prognosis. OBJECTIVE: To assess the cost‐effectiveness of surveillance, as compared to no surveillance. METHODS: In 2000,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Isaura S., Vasen, Hans F. A., Wasser, Martin N. J. M., Feshtali, Shirin, Bonsing, Bert A., Morreau, Hans, Inderson, Akin, de Vos tot Nederveen Cappel, Wouter H., van den Hout, Wilbert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Pancreas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039795/
https://www.ncbi.nlm.nih.gov/pubmed/36785917
http://dx.doi.org/10.1002/ueg2.12360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039795/
https://www.ncbi.nlm.nih.gov/pubmed/36785917
http://dx.doi.org/10.1002/ueg2.12360

Ejemplares similares